GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Total Payout Ratio

Amplia Therapeutics (Amplia Therapeutics) Total Payout Ratio : 0.00 (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Amplia Therapeutics's current Total Payout Ratio is 0.00.


Amplia Therapeutics Total Payout Ratio Historical Data

The historical data trend for Amplia Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Total Payout Ratio Chart

Amplia Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.88 1.61 4.14 -

Amplia Therapeutics Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 4.96 0.01 - -

Competitive Comparison of Amplia Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, Amplia Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Total Payout Ratio falls into.



Amplia Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Amplia Therapeutics's Total Payout Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.014 + 0) / -4.167
=0.00

Amplia Therapeutics's Total Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.726
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (Amplia Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines